HeartFlow, Inc. is a medical technology company redefining the way heart disease is diagnosed and treated. Our non-invasive HeartFlow FFRct Analysis leverages deep learning to create a personalized 3D model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. Our technology is reflective of our Silicon Valley roots and incorporates decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRct Analysis is commercially available in the United States, Canada, Europe and Japan.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/14/18 | $240,000,000 | Series E |
Baillie Gifford Wellington Management Company | undisclosed |
| 04/10/23 | $215,000,000 | Series F |
Baillie Gifford Bain Capital Life Sciences  Capricorn Investment Group Hayfin Capital Management Healthcor Partners Janus Henderson Investors Martis Capital USVP Wellington Management | undisclosed |
